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Esophageal squamous cell carcinomas (ESCCs) are highly invasive and have poor prognoses. We
investigated the role of PTPLAD2, a protein tyrosine phosphatase-like A domain (PTPLAD) family
member, in ESCC carcinogenesis. Survival analysis was performed using patient data. ESCC tissue
samples lost PTPLAD2 heterozygosity and had decreased PTPLAD2 expression. Low PTPLAD2 expression
and high p-STAT3 correlated with poor prognosis. Overexpression of PTPLAD2 in ESCC cells reduced
STAT3 phosphorylation, decreased FoxM1, inhibited proliferation and decreased in mouse xenograft
tumor formation. Therefore, PTPLAD2 is a potential tumor suppressor and prognostic indicator that
reduces STAT3 phosphorylation. PTPLAD2 is a possible clinical target for ESCC treatment.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Protein tyrosine phosphatase-like A domain-containing 2Esophageal squamous cell carcinoma (ESCC) is one of the six
most common cancers worldwide, with an annual incidence of
300000. ESCC occurs at a high frequency in China (13 per
100000) [1]. In the United States, an estimated 16980 new cases
were diagnosed in 2011. ESCC is an aggressive malignancy with a
poor prognosis [2]. Markers that can identify a high risk of ESCC
and improve the prognosis of this disease are required.(PTPLAD2) is a 232-amino acid membrane protein in the PTPLAD
family. The PTPLAD2 gene is conserved in chimpanzees, dogs,
cows, mice, rats, and chickens. In humans, the PTPLAD2 gene maps
to chromosome 9p21.3 [3]. The allelic loss of chromosome 9
potentially initiates bladder carcinoma [4]. A non-random loss of
heterozygosity (LOH) involving the 9p region has been found
[5,6]. Genetic changes such as these can result in the functional
loss of tumor suppressor genes or activation of proto-oncogenes
[7]. Analysis of many tumor types has indicated that one or more
tumor suppressor genes are located at chromosome 9p [8]; there-
fore, loss of a 9p haplotype might affect the expression of proteins
that control tumor growth [9]. Genetic alterations within 9p21
result in both familial and sporadic cases of melanoma [10]. How-
ever, the exact genes that undergo LOH at 9p are unknown. In
ESCC, LOH at 6p21.3 has been identiﬁed, which affects HLA class
I expression [11,12].
Signal transducer and activator of transcription 3 (STAT3) regu-
lates tumor cell carcinogenesis, proliferation, invasion, angiogene-
sis, and immune evasion, in addition to apoptosis [13–16]. STAT3 is
activated by phosphorylation at tyrosine 705 (Tyr705) and serine
982 S. Zhu et al. / FEBS Letters 588 (2014) 981–989727 (Ser727) by tyrosine kinases, such as Janus kinase (JAK), in re-
sponse to extracelluar cytokines and signals. Suppressor of cyto-
kine signaling 3 (SOCS3) is a negative regulator of the JAK-STAT
pathway. STAT3 is constitutively activated in many types of can-
cers, including ESCC [17–20]. Increased STAT3 activity promotes
survival, progression, and proliferation of ESCC cells in vitro and
in vivo [2,17]. However, the molecular mechanism underlying
STAT3 hyperactivation is largely unknown.
In this study, we hypothesized that PTPLAD2 is involved in ESCC
carcinogenesis. We found that ESCC patient tissue samples with
LOH at 9p had markedly lower levels of PTPLAD2. We postulate
that PTPLAD2 regulates the proliferation of ESCC cells by reducing
the phosphorylation of STAT3.
2. Materials and methods
2.1. Tissue collection
Human ESCC specimens were obtained from 213 ESCC patients
in Tangdu Hospital, Xi’an, China. Patient details are provided in
Table 1. The patient samples were collected with informed written
consent according to an established protocol. Overall patient
survival data were obtained from the local municipal registry. The
median follow-up time was 4.01 years (range: 0.11–6.03 years). All
experimental procedures were approved by the Research Ethics
Committee of Tangdu Hospital.
2.2. Laser capture micro-dissection and DNA extraction
Representative ESCC tumor specimens were selected after
examination with hematoxylin-eosin staining. Sections (10 lm)
were stained with neutral fast red for visualization with a laser-
capture microdissection instrument (Leica LMD-6000) for tumor
cell isolation. DNA was isolated from ESCC specimens (QIAamp
DNA Mini and Blood Mini; Qiagen, Valencia, CA).
2.3. Single-nucleotide polymorphism detection with high-resolution
Affymetrix microarrays
GeneChip HumanMapping 6.0 single-nucleotide polymorphism
(SNP) microarrays (SNP 6.0; Affymetrix, Inc., Santa Clara, CA) con-
tained 906600 probes for SNPs and 946000 probes for copy num-
ber variation, with a median physical intermarker distance of
680 bp. All procedures were performed and the data analyzed
according to the manufacturer’s protocols. Brieﬂy, genomic DNATable 1
Detailed information regarding the 213 ESCC patient specimens.
Detailed information No. of tumor specimens (N = 213)
Gender
Male 152
Female 61
Age (years)
>60 105
660 108
Grade
Well differentiated 72
Moderately differentiated 119
Poorly differentiated 22
Depth of tumor invasion
Mucous layer 38
Muscular layer 41
Serous layer 134
Lymph node metastasis
Absent 81
Present 132(250 ng) was digested with Nsp I and Sty I (New England Biolabs,
Inc., Ipswich, MA) and ligated to appropriate adaptors. The adap-
tor-ligated fragments were ampliﬁed, digested with DNase I,
end-labeled with a biotinylated nucleotide, and hybridized to hu-
man SNP 6.0 arrays at 49 C for 17 h. After hybridization, the arrays
were washed, stained, and scanned with a GeneChip Scanner 3000
7G (Affymetrix). LOH incidence was calculated from the ratio of the
intensities of two alleles from a tumor sample corrected by the ra-
tio from a corresponding reference DNA that was from a tumor-
free lymph node sample. A shift in the allelic ratio was interpreted
as LOH if the ﬁnal quotient was 60.6 or >1.67. All experiments
were performed in duplicate, and homozygous and non-analyzable
peaks were designated as non-informative cases.
2.4. Cell culturing and assays
Human esophageal epithelial HET-1A cells, ESCC Eca109, and
murine embryonic ﬁbroblast (NIH3T3) cells (ATCC) were cultured
in RPMI 1640 supplemented with 10% heat-inactivated fetal bo-
vine serum, 100 U/ml penicillin and 100 mg/ml streptomycin.
Cells were incubated at 37 C in a humidiﬁed atmosphere (5%
CO2). Cells were treated with 6 ng/ml recombinant human inter-
leukin (IL)-6 (Upstate Biotechnology, Lake Placid, NY) for 72 h.
The STAT3 phosphorylation inhibitor S31–201 (Calbiochem, La
Jolla, CA, USA) was added to the culture medium at 50 lM for
72 h.
Transfections were carried out as described previously [17]
with 5 lg/ml small hairpin (sh)RNA against PTPLAD2 or STAT3
(Viagene, CA, USA), unrelated control shRNA (Santa Cruz, CA,
USA), the pcDNA-PTPLAD2 plasmid (GenePharm. Co. Ltd., Shang-
hai, China), or empty plasmid. To obtain stably transfected cells,
the transfected cells were selected with G418 (Sigma, Saint Louis,
USA) at 200 lg/ml 24 h after transfection.
For colony formation assays, 500 cells were plated into 60 mm
dishes for 14 days. Colonies were washed twice with phosphate-
buffered saline, stained with 1% crystal violet, and counted. All
experiments were independently repeated three times.
2.5. MTT assay
Cell survival was determined with 3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyltetrazolium bromide (MTT) assays. Cells (5  103
cells/well) were seeded into a 96-well plate and incubated for
72 h. Treated cells were incubated with medium containing
5 mg/ml MTT (Sigma, Saint Louis, USA) for 2 h at 37 C, followed
by solubilization with 200 ml of lysis solution. Absorbance was
read at 570 nm with a microplate reader (Bio-Rad, USA).
2.6. Immunohistochemistry
Parafﬁn sections of human ESCC tissues and mice tumors were
generated and stained following standard protocols with antibod-
ies against STAT3, p-STAT3, PTPLAD2 or Ki67 (Cell Signaling, Dan-
vers, USA). Streptavidin-conjugated secondary antibody was
applied and visualized with DAB. Images were analyzed with a Lei-
ca light-ﬁeld microscope. The expression levels of PTPLAD2 and
phosphorylated STAT3 (p-STAT3) were designated as 0 (), 1 (+),
2 (++), or 3 (+++) by estimating the staining density and positive
staining rate as described previously [21].
2.7. Western blot
Western blotting was performed according to standard proto-
cols [17]. Tissues or cells were lysed in lysis buffer. After separation
on 12% SDS–polyacrylamide gels, proteins were electrotransferred
to nitrocellulose membranes, which were then blocked with 5%
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against PTPLAD2, STAT3, p-STAT3 (Tyr705), p-STAT3 (Ser727),
p-JAK2 (Tyr1007/1008), JAK2 (Cell Signaling, Danvers, USA), or
FoxM1 (Abcam, USA) overnight. The blots were washed, exposed
to horseradish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology, CA, USA) for 2 h, and examined with enhanced
chemiluminescence substrate (PerkinElmer Life Sciences). Protein
bands were quantiﬁed using TotalLab TL100 software (Non-linear
Dynamics). Anti-tubulin antibody (Santa Cruz Biotechnology, CA,
USA) was used to normalize the protein amounts.Fig. 1. PTPLAD2 is suppressed in ESCC. (A) Immunohistochemistry for PTPLAD2, STAT3
ESCC tissue. Scale bar: 50 lm. (B) Western blot for PTPLAD2, STAT3, and p-STAT3 (Ty
quantiﬁed. Tubulin was used as a loading control. (C and D) Survival curves with PTPLAD
(p-STAT3) negative expression (), Green curve: patients with PTPLAD2 (p-STAT3) weak
Positive expression (++), Purple curve: patients with PTPLAD2 (p-STAT3) strong Positive2.8. Animals
Xenografts of ESCC cells were established in mice using Eca109
cells transfected with empty vector, Eca109 cells overexpressing
PTPLAD2, or Eca109 cells overexpressing PTPLAD2 + interleukin
(IL)-6 treatment. Cells were injected subcutaneously (5  106
cells/site) into the ﬂanks of 5- to 6-week-old BABL/c nude mice
(8 mice/group). Mice with PTPLAD2-overexpressing ESCC cell
xenografts were treated daily with IL-6 at 10 lg/kg/day injected
through the tail vein. After three weeks, the mice were sacriﬁced,, p-STAT3 (Tyr705) and p-STAT3 (Ser727). Normal, adjacent normal tissue; Cancer,
r705) and p-STAT3 (Ser727) phosphorylation in patient tissues. Band density was
2 and p-STAT3 expression and patient survival. Blue curve: patients with PTPLAD2
positive expression (+), Yellow curve: patients with PTPLAD2 (p-STAT3) moderate
expression (+++).
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measured.
Mice used in these studies were housed at the Experimental
Center of Animal Research (ECAR) at the Fourth Military Medical
University (FMMU) and handled by ECAR staff. All mice were clo-
sely monitored and humanely euthanized. This study was ap-
proved by the Institutional Animal Care and Use Committee
(IACUC) of FMMU. The use of animals in this study complies with
the Guide for the Care and Use of Laboratory Animals in FMMU.
2.9. Statistical analysis
The data analysis utilized a two-tailed unpaired t-test. Values
were expressed as the mean ± standard error of the mean
(S.E.M.). A value of P < 0.01 was considered signiﬁcant. The correla-
tion between PTPLAD2 expression and p-STAT3 was analyzed with
the Spearman rank correlation coefﬁcient.3. Results
3.1. Low PTPLAD2 expression and STAT3 hyperphosphorylation in
ESCC
We examined 213 cases of ESCC for LOH involving chromosome
9. Patients details are provided in Table 1. ESCC tumor tissues were
isolated by laser microdissection and analyzed for LOH with SNP
microarrays. The microsatellite markers D9S145 and D9S146 were
used to detect LOH of chromosome 9. Of the 213 ESCC patients, 117
(55%) exhibited an allelic loss of at least one locus on the proximal
p arm of chromosome 9. These results indicated that the region be-
tween 9p21 and 9p22 might harbor tumor suppressor genes
important in ESCC carcinogenesis. Because the PTPLAD2 gene is lo-
cated at 9p21.3, we hypothesized that PTPLAD2 expression would
be altered in ESCC.
To test this hypothesis, immunohistochemistry was performed
on tissue samples from ESCC patients. We evaluated the expressionFig. 2. PTPLAD2 is crucial for controlling ESCC cell proliferation. PTPLAD2 was knocke
Proliferation of HET-1A (white) and NIH3T3 cells (black) measured with MTT and colony
with pcDNA-PTPLAD2. Con, non-transfected cells; non-related shRNA, non-related shRNA
(C and D) Proliferation of Eca109 cells measured by an MTT assay and colony formation. C
overexpression, pcDNA-PTPLAD2-transfected cells. All experiments were repeated threeof PTPLAD2, STAT3, and p-STAT3. PTPLAD2 expression was reduced
in ESCC tissues compared with adjacent normal esophageal epithe-
lial tissues. STAT3 expression did not change, but STAT3 phosphor-
ylation at Tyr705 was increased. Similarly, the Western blot results
revealed low PTPLAD2 expression levels and high levels of STAT3
phosphorylation on Tyr705 and Ser727 (Fig. 1A and B).
Decreased patient survival correlated with low PTPLAD2
expression and high STAT3 phosphorylation (Fig. 1C and D), sug-
gesting that a lack of PTPLAD2 was involved in ESCC formation
and development. In addition, PTPLAD2 negatively correlated with
STAT3 phosphorylation (R = 0.521).
3.2. PTPLAD2 inhibits proliferation of esophageal squamous cell
carcinoma cells
To investigate the function of PTPLAD2 in ESCC carcinogenesis,
PTPLAD2 expression was knocked down in a human esophageal
epithelial cell line (HET-1A) and mouse embryonic ﬁbroblasts
(NIH3T3) using shRNA. MTT and colony formation assays revealed
that the proliferation of HET-1A and NIH3T3 cells signiﬁcantly in-
creased when PTPLAD2 was depleted (Fig. 2A and B). Furthermore,
the transfection of Eca109 ESCC cells with a plasmid overexpress-
ing PTPLAD2 resulted in decreased cell survival (Fig. 2C and D).
These results suggest that PTPLAD2 is important in the prolifera-
tion of ESCC cells and ESCC carcinogenesis.
3.3. PTPLAD2 suppresses proliferation of ESCC cells by inhibiting STAT3
We next investigated the molecular mechanisms of this inhibi-
tion using a PTPLAD2 knockdown in HET-1A and NIH3T3 cells. In
these cells, STAT3 phosphorylation on Tyr705 and Ser727 was
markedly enhanced. However, neither the expression nor the
phosphorylation of JAK2, a tyrosine kinase that phosphorylates
STAT3, was changed. SOCS3, a negative regulator of STAT3, was
also unaltered in PTPLAD2-knockdown cells. Overexpression of
PTPLAD2 in ESCC cells inhibited STAT3 phosphorylation on
Tyr705 and Ser727 (Fig. 3A).d down in HET-1A and 3T3 cells by transfection with speciﬁc shRNA. (A and B)
formation assays. PTPLAD2 was overexpressed in Eca109 ESCC cells by transfection
-transfected cells; targeted shRNA, cells transfected with a shRNA against PTPLAD2.
on, non-transfected cells; empty vector, cells transfected with empty pcDNA vector;
times. Data are the means with S.E.M. ⁄P < 0.01.
Fig. 3. PTPLAD2 suppresses ESCC cell proliferation by inhibiting STAT3. (A) HET-1A and NIH3T3 cells were transfected with either control shRNA or shRNA targeted to
PTPLAD2 for 72 h; Eca109 cells were transfected with empty vector or a PTPLAD2-overexpressing vector for 72 h. Cell lysates were analyzed via Western blotting for JAK2,
SOCS, STAT3, and the phosphorylation of JAK2 (Tyr 1007/1008) or STAT3 (Tyr705 or Ser 727). Tubulin was used as a loading control. (B) PTPLAD2 or STAT3 was knocked down
in HET-1A cells using speciﬁc shRNA. STAT3 activity was inhibited with 50 lM S31-201. After 72 h, proliferation was measured with MTT. (C) Eca109 ESCC cells
overexpressing PTPLAD2 were untreated or treated with 6 ng/ml IL-6. After 72 h, proliferation was measured with MTT. All experiments were repeated three times. Data are
the means with S.E.M. ⁄P < 0.01 compared to control.
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liferation; moreover, the inhibition of STAT3 phosphorylation by
the STAT3 inhibitor S31-201 partially reversed the hyperprolifera-
tion of PTPLAD2-knockdown HET-1A cells (Fig. 3B). When ESCCcells overexpressing PTPLAD2 were incubated with IL-6, which is
known to activate STAT3 through phosphorylation of Tyr705 and
Ser727 [22–24], the inhibition of Eca109 cell proliferation was
partially reversed (Fig. 3C). These results suggest that PTPLAD2
986 S. Zhu et al. / FEBS Letters 588 (2014) 981–989inhibits ESCC cell proliferation, at least in part, through the reduc-
tion of STAT3 phosphorylation.
3.4. FoxM1 suppression with STAT3 dephosphorylation
Forkhead box M1 (FoxM1) is a key transcription factor in cell
cycle progression [25]. FoxM1 is critical for tumor development
and progression in lung, breast and colon cancer [26–28]. FoxM1
is a direct target of STAT3 and regulates proliferation, survival
and DNA repair in K562 cells [29]. We found that FoxM1 expres-
sion was higher in ESCC tissues than in adjacent normal tissue
(Fig. 4A).
In vitro, the overexpression of PTPLAD2 reduced FoxM1 expres-
sion in Eca109 cells in which STAT3 phosphorylation had beenFig. 4. STAT3 regulates FoxM1 expression in ESCC cells. (A) Western blot for FoxM1
quantiﬁed. Tubulin was used as a loading control. ⁄P < 0.01 compared to normal tissue.
vector or treated with 6 ng/ml IL-6 for 72 h. Cell lysates were analyzed via Western blott
#P < 0.01 compared to PTPLAD2-overexpressing cells. (C) Eca109 ESCC cells overexpressin
vector, or both vectors. After 72 h, proliferation was measured with MTT. All experimen
control, #P < 0.01 compared to PTPLAD2-overexpressing cells.inhibited (Fig. 4B). Activating STAT3 by incubating cells with IL-6
partially reversed the reduction in FoxM1 expression. Overexpress-
ing PTPLAD2 impaired cellular proliferation (Figs. 3C and 4C), but
overexpressing FoxM1 reversed the decrease in survival of
Eca109 cells overexpressing PTPLAD2. This suggests that FoxM1
is a downstream target of STAT3.
3.5. PTPLAD2 suppresses proliferation of ESCC cells in vivo
To examine the effects of PTPLAD2 on ESCC cell proliferation
in vivo, a vector expressing myc-tagged PTPLAD2 was transfected
into Eca109 cells. Cells transfected with an empty vector or the
myc-PTPLAD2 vector were transplanted subcutaneously into nude
mice. ESCC cells overexpressing PTPLAD2 formed fewer andexpression in patient ESCC tissues and adjacent normal tissue. Band density was
(B) Eca109 cells were transfected with empty vector or a PTPLAD2-overexpressing
ing for FoxM1. Tubulin was used as a loading control. ⁄P < 0.01 compared to control.
g PTPLAD2 were transfected with a PTPLAD2 expression vector, a FoxM1 expression
ts were repeated three times. Data are the means with S.E.M. ⁄P < 0.01 compared to
S. Zhu et al. / FEBS Letters 588 (2014) 981–989 987signiﬁcantly smaller tumors in mice compared with the control
cells, but tumor formation increased when mice were treated with
IL-6, which results in the phosphorylation and activation of STAT3
(Fig. 5).
We next determined whether PTPLAD2 inhibited ESCC cell pro-
liferation in vivo using immunohistochemistry to detect Ki67, a cell
proliferation marker, in xenograft tumors. Tumors overexpressing
PTPLAD2 had fewer Ki67-positive cells, indicating that PTPLAD2-
transfected ESCC cells proliferated less. Fewer cells were positive
for p-STAT3 in the PTPLAD2-transfected ESCC cells. This indicates
that PTPLAD2 might affect ESCC cell proliferation, at least partially,
by regulating STAT3 phosphorylation in vivo.Fig. 5. PTPLAD2 suppresses ESCC cell proliferation in vivo. Eca109 cells were transfected
were injected subcutaneously into nude mice. After three weeks, tumor xenografts were
Numbers and volumes of tumors in mice with xenografts from Eca109 cells that were c
(6 ng/ml). All experiments were repeated three times. Data are the means with S.E.M. ⁄
Expression of Ki67, STAT3, and p-STAT3 in xenograft tumors detected via immunohisto4. Discussion
In investigating the carcinogenesis of ESCC, we found LOH at
9p21.3, which maps to PTPLAD2. This LOH might result in the
downregulation of PTPLAD2 that we observed in ESCC tissue.
Low PTPLAD2 expression correlated with poor patient survival,
indicating that PTPLAD2 could be a potential prognostic marker
for ESCC. The function of PTPLAD2 in ESCC carcinogenesis is un-
known; however, depletion of PTPLAD2 in normal esophageal epi-
thelial HET-1A cells increased cell proliferation and colony
formation (Fig. 2). Exogenous PTPLAD2 expression in ESCC cells
resulted in decreased proliferation and colony formation. Thesewith a PTPLAD2-overexpressing plasmid or empty vector (control). The Eca109 cells
removed and tumor volume was measured. (A) Representative images of mice. (B)
ontrols, PTPLAD2-overexpressing, or PTPLAD2-overexpressing with IL-6 treatment
P < 0.05 compared to mice injected with control (non-transfected Eca109) cells. (C)
chemistry. Scale bar: 50 lm.
988 S. Zhu et al. / FEBS Letters 588 (2014) 981–989results suggest that PTPLAD2 is crucial for regulating ESCC cell pro-
liferation and carcinogenesis.
Zhang et al. reported that Polo-like kinase 1 (PLK1) is directly
activated by STAT3 in esophageal cancer cells, and this in turn pro-
motes STAT3 expression [17]. This positive feedback loop contrib-
utes to the development of ESCC. We found that STAT3
phosphorylation was markedly enhanced in ESCC tissues. High
levels of STAT3 phosphorylation correlated with decreased ESCC
patient survival. Statistical analysis revealed that PTPLAD2 expres-
sion negatively correlated with STAT3 phosphorylation, suggesting
that PTPLAD2 might negatively regulate STAT3 phosphorylation.
PTPLAD2 knockdown in human esophageal epithelial HET-1A cells
and mouse ﬁbroblast NIH3T3 cells led to increased STAT3
phosphorylation. The expression of exogenous PTPLAD2 in ESCC
Eca109 cells inhibited STAT3 phosphorylation, indicating a correla-
tion between PTPLAD2 and STAT3 phosphorylation. The activation
of STAT3 by IL-6 promoted ESCC cell proliferation, while the knock-
down or inhibition of STAT3 inhibited proliferation. Moreover,
STAT3 activation partially blocked the enhanced cell proliferation
that resulted from exogenous PTPLAD2 expression. STAT3 inhibi-
tion partially reduced the effect of PTPLAD2 depletion on cell
proliferation. These results suggest that PTPLAD2 regulates ESCC
cell proliferation, at least in part, through the regulation of STAT3
activity.aFOXM1, a Forkhead family member, regulates the tran-
scription of proliferation-associated genes and is vital for cell cycle
progression. FOXM1 overexpression is found in a wide range of
cancers, including breast, colorectal and lung. Tumors with high
FOXM1 expression are often poorly differentiated, highly malig-
nant, and distantly metastatic and have poor prognoses. FOXM1
inﬂuences tumor proliferation, invasion, metastasis and angiogen-
esis. FOXM1-knockdown cells arrest in G2-M phase after a heat
shock [30,31], suggesting the importance of FOXM1 in cell survival.
Recently, FOXM1 was identiﬁed as a direct target of STAT3. We
found that PTPLAD2 reduced STAT3 phosphorylation and subse-
quently inhibited FoxM1 expression, resulting in reduced cell
survival.
It is interesting to explore the mechanism by which PTPLAD2
reduced the phosphorylation of STAT3. PTPLAD2 was ofﬁcially des-
ignated as protein tyrosine phosphatase-like A domain-containing
2 based on the existence of a CXXXXXP PTP-like motif in the re-
lated PTPLA protein [32]. However, none of the members of the
PTPLA family are predicted to contain any PTP domain nor to har-
bor any phosphatase activity. Furthermore, the PTPLAD2 protein
does not even contain the essential PTP catalytic Cys. Instead,
PTPLA proteins, including PTPLAD2, harbor 3-hydroxyacyl-CoA
dehydratase (HACD) activity and are grouped as members of the
HACD protein family (PTPLAD2 is HACD4) [33]. The tumor sup-
pressor function of PTPLAD2 based on its dehydratase activity de-
serves further investigation.
In summary, we found that PTPLAD2 is crucial for regulating the
proliferation of ESCC cells. PTPLAD2 appears to function through
reducing STAT3 phosphorylation, which then inhibits FoxM1
expression. Our ﬁndings provide new insights into ESCC carcino-
genesis. PTPLAD2 is a tumor suppressor in this process and could
be a prognostic marker. PTPLAD2 might be involved in other can-
cers. Future studies are required to conﬁrm this hypothesis, includ-
ing clinical studies exploring PTPLAD2-targeted therapy.Financial competing interests
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